Pulse NanoMED MicroBeads after clot removal for stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new treatment called Pulse NanoMED MicroBeads for people who still have a blocked brain artery after a standard clot removal procedure (mechanical thrombectomy). The goal is to see if these tiny beads can clear the remaining blockage and improve blood flow to the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a large blood vessel blockage in the brain and have already had a clot removal procedure (mechanical thrombectomy), but some blockage remains.
- It has been less than 9 hours since you were last seen normal.
- You have no major bleeding disorders or active bleeding in the brain.
- You are not pregnant, breastfeeding, or have a known allergy to iron or contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specialized clot-removal treatment for people who had a mild but disabling stroke up to 24 hours ago and have a large artery blockage in the brain. The goal is to see if this precision therapy can help reduce disability and improve recovery.
This trial tests a new way to treat strokes caused by blockages in medium-sized brain arteries within 24 hours of symptom onset. It uses brain imaging to select patients who might benefit from a procedure to remove the clot.
This trial tests a new device that removes blood clots in the brain using suction. It is for people having a large-vessel ischemic stroke who can be treated within 8 hours of symptoms starting.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
Hear when a new Acute Ischemic Stroke AIS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.